PDLIM4, an actin binding protein, suppresses prostate cancer cell growth

Cancer Investigation

Volumn 27, Issue 3, 2009, Pages 264-272

  Vanaja, Donkena Krishna ^a   Grossmann, Michael E ^a   Cheville, John C ^a   Gazi, Mozammel H ^a   Gong, Aiyu ^a   Zhang, Jin San ^a   Ajtai, Katalin ^a   Burghardt, Thomas P ^a   Young, Charles Y F ^a  

^a MAYO CLINIC   (United States)

Author keywords

Actin cytoskeleton; Cell growth; LIM domain protein; Prostate cancer; Tumor suppressor gene

Indexed keywords

ACTIN BINDING PROTEIN; F ACTIN; LIM PROTEIN; MESSENGER RNA; PDLIM4 PROTEIN; PDZ PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ACTIN; DNA BINDING PROTEIN; PDLIM4 PROTEIN, HUMAN; PDLIM4 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CLONOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PDZ DOMAIN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH; XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; GENETICS; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ACTINS; ANIMALS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; HUMANS; MALE; MICE; MICE, INBRED BALB C; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 63349086623     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802406319     Document Type: Article

References (39)

1. Figueroa, J.A.; De Raad, S.; Speights, V.O.; Rinehart, J.J. Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: correlation with clinico-pathological parameters. Cancer Invest. 2001, 19(1), 28-34.
2. Dhanasekaran, S.M.; Barrette, T.R.; Ghosh, D.; Shah, R.; Varambally, S.; Kurachi, K.; Pienta, K.J.; Rubin, M.A.; Chinnaiyan, A.M. Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412(6849), 822-826. (Pubitemid 32801464)
3. LaTulippe, E.; Satagopan, J.; Smith, A.; Scher, H.; Scardino, P.; Reuter, V.; Gerald, W.L. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002, 62(15), 4499-4506.
4. Vanaja, D.K.; Cheville, J.C.; Iturria, S.J.; Young, C.Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003, 63(14), 3877-3882.
5. Vanaja, D.K.; Ballman, K.V.; Morlan, B.W.; Cheville, J.C.; Neumann, R.M.; Lieber, M.M.; Tindall, D.J.; Young, C.Y. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin. Cancer Res. 2006, 12(4), 1128-1136.
6. Welsh, J.B.; Sapinoso, L.M.; Su, A.I.; Kern, S.G.; Wang-Rodriguez, J.; Moskaluk, C.A.; Frierson, H.F., Jr.; Hampton, G.M. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 2001, 61(16), 5974-5978.
7. Varambally, S.; Yu, J.; Laxman, B.; Rhodes, D.R.; Mehra, R.; Tomlins, S.A.; Shah, R.B.; Chandran, U.; Monzon, F.A.; Becich, M.J.; Wei, J.T.; Pienta, K.J.; Ghosh, D.; Rubin, M.A.; Chinnaiyan, A.M. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005, 8(5), 393-406.
8. Yu, Y.P.; Landsittel, D.; Jing, L.; Nelson, J.; Ren, B.; Liu, L.; McDonald, C.; Thomas, R.; Dhir, R.; Finkelstein, S.; Michalopoulos, G.; Becich, M.; Luo, J.H. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 2004, 22(14), 2790-2799.
9. Boumber, Y.A.; Kondo, Y.; Chen, X.; Shen, L.; Gharibyan, V.; Konishi, K.; Estey, E.; Kantarjian, H.; Garcia-Manero, G.; Issa, J.P. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res. 2007, 67(5), 1997-2005.
10. Baird, K.; Davis, S.; Antonescu, C.R.; Harper, U.L.; Walker, R.L.; Chen, Y.; Glatfelter, A.A.; Duray, P.H.; Meltzer, P.S. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005, 65(20), 9226-9235. (Pubitemid 41507988)
11. Henderson, S.R.; Guiliano, D.; Presneau, N.; McLean, S.; Frow, R.; Vujovic, S.; Anderson, J.; Sebire, N.; Whelan, J.; Athanasou, N.; Flanagan, A.M.; Boshoff, C. A molecular map of mesenchymal tumors. Genome. Biol. 2005, 6(9), R76.
12. Webber, M.M.; Bello, D.; Kleinman, H.K.; Hoffman, M.P. Acinar differentiation by nonmalignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 1997, 18(6), 1225-1231.
13. Hunter, C.S.; Rhodes, S.J. LIM-homeodomain genes in mammalian development and human disease. Mol. Biol. Rep. 2005, 32(2), 67-77.
14. te Velthuis, A.J.; Bagowski, C.P. PDZ and LIM domain-encoding genes: molecular interactions and their role in development. Scientific World Journal 2007, 7, 1470-1492.
15. Xia, H.; Winokur, S.T.; Kuo, W.L.; Altherr, M.R.; Bredt, D.S. Actinin-associated LIM protein: identification of a domain interaction between PDZ and spectrin-like repeat motifs. J. Cell Biol. 1997, 139(2), 507-515.
16. Guy, P.M.; Kenny, D.A.; Gill, G.N. The PDZ domain of the LIM protein enigma binds to beta-tropomyosin. Mol. Biol. Cell 1999, 10(6), 1973-1984.
17. Vallenius, T.; Luukko, K.; Makela, T.P. CLP-36 PDZ-LIM protein associates with nonmuscle alpha-actinin-1 and alpha-actinin-4. J. Biol. Chem. 2000, 275(15), 11100-11105.
18. Vallenius, T.; Makela, T.P. Clik1: a novel kinase targeted to actin stress fibers by the CLP-36 PDZ-LIM protein. J. Cell Sci. 2002, 115(Pt 10), 2067-2073.
19. Kang, S.; Xu, H.; Duan, X.; Liu, J.J.; He, Z.; Yu, F.; Zhou, S.; Meng, X.Q.; Cao, M.; Kennedy, G.C. PCD1, a novel gene containing PDZ and LIM domains, is overexpressed in several human cancers. Cancer Res. 2000, 60(18), 5296-5302.
20. Tobias, E.S.; Hurlstone, A.F.; MacKenzie, E.; McFarlane, R.; Black, D.M. The TES gene at 7q31.1 is methylated in tumours and encodes a novel growth-suppressing LIM domain protein. Oncogene 2001, 20(22), 2844-2853.
21. Fujimoto, N.; Yeh, S.; Kang, H.Y.; Inui, S.; Chang, H.C.; Mizokami, A.; Chang, C. Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J. Biol. Chem. 1999, 274(12), 8316-8321.
22. Muller, J.M.; Isele, U.; Metzger, E.; Rempel, A.; Moser, M.; Pscherer, A.; Breyer, T.; Holubarsch, C.; Buettner, R.; Schule, R. FHL2, a novel tissue-specific coactivator of the androgen receptor. Embo. J. 2000, 19(3), 359-369. (Pubitemid 30072606)
23. Gao, J.; Arbman, G.; Rearden, A.; Sun, X.F. Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer. Neoplasia 2004, 6(6), 796-801. (Pubitemid 40041498)
24. Chene, L.; Giroud, C.; Desgrandchamps, F.; Boccon-Gibod, L.; Cussenot, O.; Berthon, P.; Latil, A. Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene. Int. J. Cancer 2004, 111(5), 798-804. (Pubitemid 39062907)
25. Sharp, T.V.; Munoz, F.; Bourboulia, D.; Presneau, N.; Darai, E.; Wang, H.W.; Cannon, M.; Butcher, D.N.; Nicholson, A.G.; Klein, G.; Imreh, S.; Boshoff, C. LIM domains-containing protein 1 (LIMD1), a tumor suppressor encoded at chromosome 3p21.3, binds pRB and represses E2F-driven transcription. Proc. Natl. Acad. Sci. USA 2004, 101(47), 16531-16536.
26. Kim, A.C.; Peters, L.L.; Knoll, J.H.; Van Huffel, C.; Ciciotte, S.L.; Kleyn, P.W.; Chishti, A.H. Limatin (LIMAB1), an actin-binding LIM protein, maps to mouse chromosome 19 and human chromosome 10q25, a region frequently deleted in human cancers. Genomics 1997, 46(2), 291-293.
27. Song, Y.; Maul, R.S.; Gerbin, C.S.; Chang, D.D. Inhibition of anchorage-independent growth of transformed NIH3T3 cells by epithelial protein lost in neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton. Mol. Biol. Cell 2002, 13(4), 1408-1416.
28. van den Berk, L.C.; van Ham, M.A.; te Lindert, M.M.; Walma, T.; Aelen, J.; Vuister, G.W.; Hendriks, W.J. The interaction of PTP-BL PDZ domains with RIL: an enigmatic role for the RIL LIM domain. Mol. Biol. Rep. 2004, 31(4), 203-215.
29. Cuppen, E.; van Ham, M.; Wansink, D.G.; de Leeuw, A.; Wieringa, B.; Hendriks, W. The zyxin-related protein TRIP6 interacts with PDZ motifs in the adaptor protein RIL and the protein tyrosine phosphatase PTP-BL. Eur. J. Cell Biol. 2000, 79(4), 283-293.
30. Sasso, F.C.; Carbonara, O.; Persico, E.; D'Ambrosio, R.; Coppola, L.; Nasti, R.; Campana, B.; Moschella, S.; Torella, R.; Cozzolino, D. Increased vascular endothelial growth factor mRNA expression in the heart of streptozotocin-induced diabetic rats. Metabolism 2003, 52(6), 675-678. (Pubitemid 36903150)
31. Bashirova, A.A.; Markelov, M.L.; Shlykova, T.V.; Levshenkova, E.V.; Alibaeva, R.A.; Frolova, E.I. The human RIL gene: mapping to human chromosome 5q31.1, genomic organization, and alternative transcripts. Gene 1998, 210(2), 239-245. (Pubitemid 28171446)
32. Le Beau, M.M.; Espinosa, R., 3rd; Neuman, W.L.; Stock, W.; Roulston, D.; Larson, R.A.; Keinanen, M.; Westbrook, C.A. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc. Natl. Acad. Sci. USA 1993, 90(12), 5484-5488.
33. Yeh, B.J.; Rutigliano, R.J.; Deb, A.; Bar-Sagi, D.; Lim, W.A. Rewiring cellular morphology pathways with synthetic guanine nucleotide exchange factors. Nature 2007, 447(7144), 596-600.
34. Tamura, N.; Ohno, K.; Katayama, T.; Kanayama, N.; Sato, K. The PDZ-LIM protein CLP36 is required for actin stress fiber formation and focal adhesion assembly in BeWo cells. Biochem. Biophys. Res. Commun. 2007, 364(3), 589-594.
35. Vallenius, T.; Scharm, B.; Vesikansa, A.; Luukko, K.; Schafer, R.; Makela, T.P. The PDZ-LIM protein RIL modulates actin stress fiber turnover and enhances the association of alpha-actinin with F-actin. Exp. Cell Res. 2004, 293(1), 117-128.
36. Lamalice, L.; Le Boeuf, F.; Huot, J. Endothelial cell migration during angiogenesis. Circ. Res. 2007, 100(6), 782-794.
37. Meyers, J.R.; Corwin, J.T. Shape change controls supporting cell proliferation in lesioned mammalian balance epithelium. J. Neurosci. 2007, 27(16), 4313-4325.
38. Pollock, C.B.; Shirasawa, S.; Sasazuki, T.; Kolch, W.; Dhillon, A.S. Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res. 2005, 65(4), 1244-1250.
39. Barros, J.C.; Marshall, C.J. Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton. J. Cell Sci. 2005, 118(Pt 8), 1663-1671.